23Na chemical shift imaging and Gd enhancement of myocardial edema.
Myocardial edema can arise in several disease states. MRI contrast agent can accumulate in edematous tissue, which complicates differential diagnosis with contrast-enhanced (CE)-MRI and might lead to overestimation of infarct size. Sodium Chemical Shift Imaging ((23)Na-CSI) may provide an alternative for edema imaging. We have developed a non-infarct, isolated rat heart model with two levels of edema, which was studied with (23)Na-CSI and CE-MRI. In edematous, but viable tissue the extracellular sodium (Na (e) (+)) signal is hypothesized to increase, but not the intracellular sodium (Na (i) (+)) signal. Isolated hearts were perfused at 60 (n = 6) and 140 mmHg (n = 5). Dimethyl methylphosphonate (DMMP) and phenylphosphonate (PPA) were used to follow edema formation by (31)P-MR Spectroscopy. In separate groups, Thulium(III)1,4,7,10 tetraazacyclododecane-N,N',N″,N'''-tetra(methylenephosphonate) (TmDOTP(5-)) and Gadovist were used for (23)Na-CSI (n = 8) and CE-MRI (n = 6), respectively. PPA normalized signal intensity (SI) was higher at 140 versus 60 mmHg, with a ratio of 1.27 ± 0.12 (p < 0.05). The (DMMP-PPA)/dry weight ratio, as a marker of intracellular volume, remained unchanged. The mid-heart cross sectional area (CSA) of the left ventricle (LV) was significantly increased at 140 mmHg. In addition, at 140 mmHg, the LV Na (e) (+) SI increased with a 140 mmHg/60 mmHg ratio of 1.24 ± 0.18 (p < 0.05). Na (i) (+) SI remained essentially unchanged. With CE-MRI, a subendocardially enhanced CSA was identified, increasing from 0.20 ± 0.02 cm(2) at 60 mmHg to 0.31 ± 0.02 cm(2) at 140 mmHg (p < 0.05). Edema shows up in both CE-MRI and Na (e) (+) . High perfusion pressure causes more edema subendocardially than subepicardially. (23)Na-CSI is an attractive alternative for imaging of edema and is a promising tool to discriminate between edema, acute and chronic MI.
Laboratory of Experimental Cardiology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands. e.n.e.aguor@umcutrecht.nl
Eissa N E
EN
Aguor
Cees W A
CW
van de Kolk
Fatih
F
Arslan
Marcel G J
MG
Nederhoff
Pieter A F M
PA
Doevendans
Gerard
G
Pasterkamp
Gustav J
GJ
Strijkers
Cees J A
CJ
van Echteld
D000818:Animals; D003287:Contrast Media; D003937:Diagnosis, Differential; D004489:Edema, Cardiac / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D066298:In Vitro Techniques; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D010477:Perfusion; D011237:Predictive Value of Tests; D051381:Rats; D017208:Rats, Wistar; D012975:Sodium Isotopes; D013997:Time Factors
D003287:Contrast Media; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D012975:Sodium Isotopes; C069929:thulium(III) 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetramethylenephosphonate; C090600:gadobutrol